Korro Bio (NASDAQ:KRRO) aims to "discover, develop and commercialize a new class of RNA therapies informed by human genetics ...
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECHâ„¢ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
The first two and some forms of obesity are associated with single-point mutations. Some other companies using ADAR enzymes ...
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 ...
Vertex may have pivoted away from the space, but candidates in development by Arrowhead/Takeda, Wave, Korro and others could ...
As the state prepares to begin phasing out fossil-fuel-powered vehicles (Zero-emission rules for trucks will be bad for business, Senate Republicans say; Oct. 10), there’s still a long road to ...
Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines, particularly for Alpha-1 Antitrypsin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback